🇺🇸 FDA

Company profile · Sponsor

CuraTeQ

CuraTeQ Biologics s.r.o

EFEBD70 · EMA pharma EU
Pipeline
2
Drugs
0
Patents
0

Quick answer

CuraTeQ (EFEBD70) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EFEBD70
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (2)

Search pipeline →

  1. Lucentis 10 mg/ml solution for injection, Ranibizumab

    CuraTeQ

    wet macula degeneration

    phase 3 small molecule active

    1 trial

  2. Xolair 150 mg solution for injection in pre-filled syringe, Placebo, solution for injection in pre-filled syringe, BP11

    CuraTeQ

    Chronic Urticaria

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is CuraTeQ?

CuraTeQ (EFEBD70) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does CuraTeQ sponsor?

We track 2 ClinicalTrials.gov-linked programs for CuraTeQ, including Lucentis 10 mg/ml solution for injection, Ranibizumab and 1 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does CuraTeQ company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.